|
Market Closed -
Nasdaq
23:00:00 13/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 68.88 USD | -1.62% |
|
+5.43% | -15.88% |
| 08-12 | Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating | MT |
| 08-07 | Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating | MT |
Company Valuation: Tarsus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 465.2 | 391 | 670.4 | 2,117 | 3,476 | 3,023 | - | - |
| Change | - | -15.95% | 71.44% | 215.74% | 64.21% | -13.04% | - | - |
| Enterprise Value (EV) | 465.2 | 391 | 472.1 | 1,894 | 3,476 | 3,023 | 3,023 | 3,023 |
| Change | - | -15.95% | 20.74% | 301.19% | 83.5% | -13.04% | 0% | 0% |
| P/E | -33.6x | -5.82x | -4.38x | -18x | -51.5x | -29.1x | 33.1x | 14.4x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0.5x | 1.1x | -0.6x | -0x | 0x |
| Capitalization / Revenue | 8.16x | 15.1x | 38.4x | 11.6x | 7.7x | 4.23x | 3.28x | 2.7x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 4.23x | 3.28x | 2.7x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -32.6x | 19.8x | 7.36x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -26.7x | 27.8x | 10.3x |
| EV / FCF | 0x | - | - | - | -0x | -26.4x | 86.7x | 13.7x |
| FCF Yield | 0.68% | - | - | - | -0.64% | -3.79% | 1.15% | 7.31% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -2.365 | 2.078 | 4.79 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 57.03 | 25.82 | 17.45 | 183 | 451.4 | 715.3 | 920.8 | 1,120 |
| EBITDA 1 | -11.84 | -62.39 | -142.3 | -119.8 | -69.15 | -92.72 | 152.4 | 410.8 |
| EBIT 1 | -12.16 | -62.71 | -143.2 | -120.6 | -70.97 | -113.3 | 108.8 | 292.2 |
| Net income 1 | -13.83 | -62.09 | -135.9 | -115.6 | -66.42 | -106.7 | 105.1 | 263.5 |
| Net Debt | - | - | -198.3 | -222.5 | - | - | - | - |
| Reference price 2 | 22.50 | 14.66 | 20.25 | 55.37 | 81.88 | 68.88 | 68.88 | 68.88 |
| Nbr of stocks (in thousands) | 20,677 | 26,672 | 33,105 | 38,227 | 42,449 | 43,883 | - | - |
| Announcement Date | 3/14/22 A | 3/13/23 A | 2/27/24 A | 2/25/25 A | 2/23/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -29.12x | - | - | -.--% | 3.02B | |
| 18.66x | 4.35x | 10.25x | 0.48% | 80.48B | |
| 38.08x | 13.03x | 24.79x | -.--% | 51.06B | |
| 21.94x | 4.85x | 13.86x | 0.66% | 48.19B | |
| -52.01x | 3.59x | 10.62x | 2.94% | 46.5B | |
| 37.43x | 3.46x | 13.16x | -.--% | 31.12B | |
| -7.42x | 10.33x | -6.67x | -.--% | 25.41B | |
| 53.09x | 3.4x | 26.31x | -.--% | 24.43B | |
| 70.88x | 6.81x | 45.49x | -.--% | 21.11B | |
| 23.51x | 5.06x | 13.17x | -.--% | 16.28B | |
| Average | 17.51x | 6.10x | 16.78x | 0.41% | 34.76B | |
| Weighted average by Cap. | 17.69x | 6.08x | 15.41x | 0.6% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TARS Stock
- Valuation Tarsus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
